Testing a new cell therapy for relapsed lymphoma with CD20/CD22
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have relapsed or treatment-resistant mature B-cell NHL that tests positive for CD20 and/or CD22
- Usually, be able to do most daily activities (ECOG 0–1)
- Have had at least 2 prior treatments for your lymphoma (not more than 4 prior lines)
- Your lymphoma subtype must match what the study allows (not include CLL/SLL, Richter’s from CLL/SLL, Burkitt’s, or Waldenström)
- You must have received specific prior therapies for your subtype (for example, anti-CD20 plus chemo, and other subtype-specific treatments)
- You generally must not have had certain recent treatments, like other investigational drugs, new approved therapies, radiation (with limited exceptions), or other cell/gene therapies within set time windows
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new B-cell Non-Hodgkin Lymphoma (B-NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.